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Abstract
 .Catecholamine depletion, evoked by reserpine, dramatically impaired 5-fold the testosterone-induced increase of
 .ornithine decarboxylase ODC activity in female mouse kidney. However, reserpine did not prevent kidney hypertrophy
evoked by testosterone. This is evidenced by the activity of sensitive, biochemical markers of renal hypertrophy, namely
 .arginase and ornithine aminotransferase OAT , that responded with the increase and decrease of activities to testosterone
w xtreatment, respectively 1 . Arginine and ornithine, substrates andror products of marker enzymes, showed a striking
homeostasis as their level was not affected by testosterone and reserpine, and only slightly by DFMO. Northern blot
analysis revealed that the ODC mRNA level, that was increased 10-fold by testosterone, was decreased 2-fold in
catecholamine-depleted hypertrophic kidney. Thus, ODC transcript level, lowered by reserpine, correlated partially with an
attenuated response of ODC activity to testosterone. This was in contrast to DFMO, which inhibited ODC activity, but
significantly increased its mRNA content. It is concluded that catecholamines could be involved together with testosterone
in regulation of the ODC gene expression in mouse kidney. q 1997 Elsevier Science B.V. All rights reserved.
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1. Introduction
The metabolic state and physiological response of
a cell or a tissue is controlled by a diverse set of
extracellular signals such as hormones, neurotrans-
mitters or growth factors. Mouse kidney is a well
known example of an androgen-responsive organ in
which testosterone induces a spectacular expression
 w x.of the ODC gene and several proteins e.g. 2,3 , and
Abbreviations: ODC, ornithine decarboxylase; OAT, ornithine
aminotransferase; DFMO, a-difluoromethylornithine
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evokes a complex anabolic response leading to renal
w xhypertrophy 1,4,5 .
The action of steroid hormones, including testos-
terone, is mediated by intracellular receptors that are
ligand-dependent transcription factors belonging to a
w xlarge superfamily of nuclear receptors 6–13 . Ac-
cording to the accepted view, receptor activation
 .leads to modulation of specific gene s expression
and this was believed to be dependent on steroid
ligand-binding only. However, there is a growing
body of evidence that the steroid receptor can be
activated alternatively from the cell surface by cate-
cholamines acting via their plasma membrane recep-
w xtors that initiate phosphorylation cascades 14–16 .
Thus, the transcriptional activation of a target gene
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may be affected synergistically by the steroid hor-
w xmone and neurotransmitter interplay 16 . The impor-
tance of catecholamines in the stimulation of ODC
activity by steroid hormones was indeed shown in the
w x w xliver 17,18 and kidneys 19 .
In the present paper we studied the effect of
catecholamine depletion, evoked by reserpine treat-
ment, on the testosterone-induced changes of ODC in
mouse kidney. As simple measurements of enzymatic
activity give little information about the molecular
mechanism of enzyme regulation, we also examined
the level of ODC mRNA in hypertrophic, cate-
cholamine depleted kidneys, and compared it to that
found in kidneys from animals treated with DFMO,
an irreversible ODC inhibitor. Additionally, we ex-
amined the renal level of ornithine, the substrate of
ODC, and its precursor, arginine in reserpine- and
DFMO-treated mice.
Catecholamine depleted mouse kidney, with signif-
icantly reduced ODC response to androgen, appeared
to be an excellent, novel experimental model suitable
for the verification of the mediatory role of ODC in
the hypertrophic kidney growth. Previously, we docu-
mented the testosterone induced differential changes
in renal activity of arginase and OAT — the enzymes
involved in the formation and utilization of ornithine,
w xrespectively 1 . In this study both enzymes were
used as sensitive, biochemical markers of kidney
hypertrophy.
2. Materials and methods
2.1. Experimental animals
Swiss female mice, 3 mth old, were injected with
 .testosterone 125 mgrkg, s.c. dissolved in soybean
 .oil controls received soybean oil only . Reserpine
 .10 mgrkg, i.p. was injected 1 h before testosterone.
DFMO was administered as a 3% solution in the
drinking water starting 24 h before testosterone injec-
tion. The mice were sacrificed by cervical dislocation
5 days after testosterone treatment, if not stated other-
wise. The kidneys were removed, weighed and cut
into several pieces.
2.2. Enzyme acti˝ity and amino acid determination
The kidney pieces were immediately homogenized
in an appropriate buffer and further processed for
enzyme activity determinations as previously de-
w xscribed 1 , or were frozen at y708C and processed
for HPLC amino acid determination as described
w x20 , and for estimation of ODC mRNA. The protein
concentration was estimated according to the method
w xof Lowry et al. 21 .
2.3. Northern blot analysis
Total kidney RNA was isolated according to
w xChomczynski and Sacchi 22 . Purified RNA samples
were electrophoresed in formaldehyde-denaturing gels
 .1% wrv, agarose overnight at 20 V and blotted
onto a nylon membrane. The filters were prehy-
bridized for 2 h, and hybridized with pODC 934
w x 32probe 23 P-labelled by the random primer
. method overnight at 658C in Church buffer 1%
 .bovine serum albumin BSA , 7% SDS, 0.5 M sodium
.phosphate buffer, pH 6.5, 1 mM EDTA , and washed
twice in a solution containing 0.5% BSA, 5% SDS,
40 mM sodium phosphate buffer, pH 6.5, 1 mM
EDTA, and again twice in 1% SDS, 40 mM sodium
phosphate buffer, pH 6.5, 1 mM EDTA. The filters
were exposed to autoradiography films with the use
Table 1
The effect of reserpine on ODC, arginase and OAT activities in testosterone-induced hypetrophic mouse kidney
Treatment Specific activity
 .  .  .ODC nmolrh per mg protein Arginase mmolrh per mg protein OAT mmolrh per mg protein
 .  .  .Control 0.3"0.4 10 29.1"5.2 10 0.62"0.13 10
 .  .  .Testosterone 132.0"61.4 10 45.1"13.2 10 0.28"0.06 10
 .  .  .Testosteroneq reserpine 22.9"15.9 13 35.6"7.7 13 0.28"0.05 13
The results are expressed as means"S.D.; the number of mice is given in parentheses. The data were processed by Mann-Whitney test;
 .effect of testosterone vs. control was P-0.0001, P-0.001 and P-0.001 for ODC, arginase and OAT, respectively; effect of
 .reserpine vs. testosterone was P-0.001, NS and NS for ODC, arginase and OAT, respectively; NS, non-significant.
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of intensifying screens at y708C. ODC mRNA levels
were quantitated by densitometric scanning of the
autoradiograms using a Molecular Dynamics Per-
 .sonal Laser Densitometer ImageQuant software and
corrected for total RNA loaded onto the gels as
determined by ethidium bromide staining of 28S
rRNA.
2.4. Chemicals
All chemicals purchased from commercial sources
were of analytical grade. Testosterone was obtained
 . from Polfa Poland , reserpine and gabaculine 3-
.amino-2,3-dihydrobenzoic acid from Sigma. DFMO
was a gift from Marion Merrell Dow Research Insti-
tute, Strasbourg, France. Rediprime Random Primer
. w 32 xLabelling , Hybond-N, Hyperfilm-MP, a P dCTP
 . w 14 x110 TBqrmmol , DL- 1- C ornithine hydrochloride
 . w 14 x2.07 GBqrmmol and L- U- C arginine monohy-
 .drochloride 11.8 GBqrmmol were obtained from
Amersham.
3. Results
3.1. Effect of reserpine on ODC acti˝ity and testos-
terone-induced kidney hypertrophy
Reserpine, a drug known to produce catecholamine
depletion, prevented the spectacular increase of ODC
activity induced by testosterone in female mouse
 .kidney to a large extent Table 1 . Thus, in the
presence of reserpine and testosterone ODC activity
reached less than 20% of activity induced by the
steroid alone. A similar effect of reserpine 18.1%"
Table 2
Reserpine effect on the testosterone-induced kidney enlargement
) ))Treatment Relative kidney wt. P P
 .Control 1.17"0.12 10 – –
 .Testosterone 1.27"0.09 10 -0.05 –
 .Testosteroneqreserpine 1.34"0.11 17 -0.01 NS
Relative kidney weight is expressed as percentage of body weight
in the final day of experiment. The results are expressed as
mean"S.D.; the number of mice is given in parentheses. The
 )data were processed by Mann-Whitney test P -calculated vs.
)) .control; P -calculated vs. testosterone-treated mice ; NS, non-
significant.
Table 3
The effect of reserpine and DFMO on arginine and ornithine
level in testosterone-induced hypertrophic kidney
Treatment nmolrg wet wt.
Arginine Ornithine
 .  .Control 147.5"34.7 13 142.1"21.7 16
 .  .Testosterone 145.7"18.8 12 NS 126.1"23.1 12 NS
 .  .Testosteroneq 152.7"12.4 8 NS 132.9"26.1 8 NS
reserpine
)) .  .Testosteroneq 116.5"4.6 5 116.7"9.8 5 NS
DFMO
The results are expressed as means"S.D.; the number of mice is
given in parentheses. The data were processed by Mann-Whitney
test; effect of testosterone was calculated vs. control, effect of
reserpine and DFMO vs. testosterone.
NS, non-significant; )) P -0.01.
 ..15.4 13 was observed when the time of testos-
terone treatment was shortened from 5 days to 65 h.
We have previously shown that in female mice
testosterone exerted an opposite effect on the activity
Fig. 1. The effect of testosterone and DFMO on ODC mRNA
level as demonstrated by Northern blot analysis. 18S and 28S
rRNA ethidium bromide stained bands indicating the amount of
RNA blotted onto the filter are shown below.
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of the other two enzymes involved in argininerorni-
w xthine metabolism, namely arginase and OAT 1 .
Thus, in this sex of mice the activities of arginase and
OAT were considered as sensitive biochemical mark-
ers of kidney hypertrophy. Table 1 shows that the
arginase and OAT activities were increased and de-
creased, respectively, due to testosterone treatment.
However, in contrast to ODC, reserpine did not sig-
nificantly change the activities of the above marker
enzymes in androgen-induced hypertrophic kidney.
It has to be noted that the above results which
pointed to the insensitivity of testosterone-evoked
kidney hypertrophy to catecholamine depletion, were
further confirmed by kidney enlargement. Table 2
shows that reserpine did not prevent the enlargement
of the kidney induced by androgen; in fact the rela-
tive kidney weight was even slightly higher after the
administration of reserpine, probably due to weight
loss observed in reserpine-treated mice.
3.2. Arginine and ornithine content in hypertrophic
kidney; effect of reserpine and DFMO ˝s. gabaculine
The profound changes in the activity of the essen-
tial enzymes of the argininerornithine pathway in-
w xduced by testosterone in the kidney 1 remained
without any effect on arginine and ornithine renal
 .levels Table 3 . The effect of reserpine and DFMO,
inhibitors of ODC activity although acting through
.different mechanisms , was further examined. In the
hypertrophic kidney arginine and ornithine levels were
unchanged by reserpine, whilst DFMO caused a slight
decrease of both amino acid content. This appeared to
be statistically significant only in the case of arginine
 .Table 3 .
In order to verify the above unexpected results
pointing to the striking homeostasis of renal arginine,
and especially ornithine, we performed a control
experiment and examined the effect of gabaculine —
known to increase ornithine tissue content and a
w xstrong inhibitor of OAT 24 . Our results were similar
w x to an earlier report 24 ; we found that gabaculine 50
.mgrkg, i.p.; administered twice for 24 h and 2 h
increased the ornithine level, which reached 173.1%
 ."13.2 3 of the control value. Moreover this in-
hibitor caused 80% decrease of OAT activity and had
no effect on arginase activity and on arginine content.
3.3. Differential effect of reserpine and DFMO on
ODC mRNA steady-state le˝el
In order to understand the mechanism of
reserpine-induced changes of ODC activity in hyper-
trophic kidney we examined the level of ODC mRNA
 .by Northern blot analysis Figs. 1–3 . The effect of
reserpine was further compared with that of DFMO.
As Figs. 1 and 3A show, the accumulation of ODC
mRNA was increased several times in testosterone-
induced hypertrophic kidney. Reserpine administered
prior to testosterone lowered the ODC transcript level
 .2-fold Figs. 2 and 3B . This decrease, although
significant, was however less pronounced than the
drop of ODC activity under the same conditions.
In contrast to reserpine, DFMO increased the ODC
 .mRNA level in the control 2.7-fold and in hyper-
 .  .trophic kidney 1.5-fold , Figs. 1 and 3 . Thus, in
spite of a similar effect of reserpine and DFMO on
Fig. 2. The effect of reserpine on ODC mRNA level in testos-
terone-induced hypertrophic kidney as demonstrated by Northern
blot analysis. 18S and 28S rRNA ethidium bromide stained bands
indicating the amount of RNA blotted onto the filter are shown
below.
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Fig. 3. Relative ODC mRNA level in mouse kidney. A, effect of DFMO and testosterone vs. control; B, effect of reserpine and DFMO
vs. testosterone in testosterone-induced hypertrophic kidney. Results are expressed as means"S.D.. The data by Mann-Whitney test; P
 . ) )) )))values vs. control and testosterone in A and B, respectively , P-0.05; , P-0.01; , P-0.001.
ODC activity, both compounds differentially modu-
lated the level of ODC message.
4. Discussion
Hypertrophic and hyperplastic renal growth and
the role of polyamines in these processes have been
w xthoroughly studied in this laboratory 1,4,5,20,25 . So
far, structural analogues of ornithine or polyamines
 .including the best known DFMO , potent inhibitors
of polyamine metabolism, were irreplaceable in the
evaluation of the critical role of polyamines in the
regulated organ growth. In this study another ap-
proach to inhibit ODC activity in testosterone-induced
hypertrophic mouse kidney model was used. We
applied reserpine, known to deplete catecholamines,
to dramatically impair the androgen-induced ODC
activity — thus confirming the recent report by
w xCremades et al. 19 .
After testosterone treatment, the catecholamine-de-
pleted female mouse kidney with impaired ODC
.activity underwent hypertrophy similar to reserpine-
w xuntreated and DFMO-treated mice 1 . Hypertrophy
was evaluated both by kidney enlargement and by
more precise biochemical events accompanying renal
w xhypertrophic but not hyperplastic growth 1 —
namely by the coinduced with ODC arginase activity
and the decreased activity of OAT. The observed
renal hypertrophy, occurring under conditions of par-
tially inhibited ODC activity due to reserpine treat-
ment, provides additional confirmation that full ODC
induction is not a prerequisite for hypertrophic growth
w x1,5,25 . Similarly, the renal growth independence of
the induced ODC activity was observed in different
w xmodels of renal hypertrophy in mice 26–28 . Insen-
sitivity of kidney hypertrophy to ODC inhibition
evoked by reserpine was in contrast to antifolate-in-
duced renal hyperplasia that was responsive to cate-
w xcholamine depletion unpublished data .
In hypertrophic kidney, androgen induces pro-
found changes in the metabolism of polyamine pre-
 .cursors i.e. arginine and ornithine by augmentation
of polyamine biosynthesis, enhancing the formation
of ornithine from arginine, and decreasing the chan-
neling of ornithine into the glutamaterproline path-
w xway 1 . However, all these changes of ODC, arginase
and OAT activities do not influence the renal level of
arginine and ornithine, the essential metabolites of
the pathway. The homeostasis of ornithine and argi-
nine was also fully preserved under the conditions of
reserpine-inhibited ODC activity, whilst DFMO only
slightly lowered the arginine content and did not
affect significantly ornithine level. Moreover, the
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level of the two amino acids was not changed by
developing ascitic tumour, and only to a minor extent
w xby a solid one 20 . These striking results were
positively verified in the experiments with the use of
gabaculine. As expected, this non-specific inhibitor
of OAT activity, in accordance with earlier reports
w x24,29,30 , caused a considerable increase of renal
ornithine concentration. Similarly, the ornithine tissue
level was greatly enhanced by 5-fluoromethyl-
w xornithine, the first specific inhibitor of OAT 31,32
which points to the importance of OAT in ornithine
homeostasis.
In mammalian tissues many trophic responses are
mediated by catecholamines. As catecholamines are
also believed to activate steroid receptors in a
w xligand-independent manner 14–16 their involve-
ment in ODC induction by testosterone in kidney, an
androgen responsive organ, was not unexpected. Thus,
in catecholamine-depleted mouse kidney the response
of ODC activity to testosterone was markedly attenu-
 w x.ated this paper, 19 , while in rat liver the depletion
of catecholamines or the blocked adrenoreceptors
prevented stimulation of ODC activity by glucocorti-
w xcoid and laparotomy 17,18 . Similarly, in rat seminal
vesicle epithelial cells androgens were only able to
induce synthesis of tissue specific secretory proteins
w xin the presence of neurotransmitters 33 .
To obtain an insight into the catecholamine modu-
lation of ODC at the molecular level the content of
ODC mRNA in reserpine-treated hypertrophic kidney
was examined. The well established striking elevation
of the ODC message by testosterone connected with
the increased transcription rate of the ODC gene and
w xtranscript stabilization 3,23,34–36 was observed.
Although both reserpine and DFMO impaired tes-
tosterone-induced renal ODC activity Northern blot
analysis revealed their differential effect on ODC
mRNA level. Thus, reserpine significantly decreased
ODC gene expression in hypertrophic kidney; a simi-
lar effect was observed in antifolate-induced hyper-
w xplastic kidney unpublished data . In contrast, DFMO
increased both the basal and testosterone-induced
ODC message in kidney in a similar way to human
w xcolon carcinoma cells 37–39 . This increase of ODC
mRNA accumulation occurred in spite of the de-
creased transcription of the ODC gene and was con-
nected with post-transcriptional stabilization of a
w xtranscript 38 .
The marked decrease of ODC gene expression in
catecholamine-depleted hypertrophic kidney corre-
lated, although only in part, with the impaired ODC
activity. Since the observed decrease in the ODC
mRNA level did not fully account for a 5-fold de-
crease in ODC activity it is possible that catechol-
amines might be involved in the modulation of multi-
ple mechanisms responsible for the altered ODC
activity in testosterone-induced hypertrophic kidney.
Moreover, catecholamines seem to serve an important
role in a complex process of regulation of ODC gene
expression in steroid-independent experimental mod-
w xels such as regenerating rat liver 40 , or antifolate-in-
 .duced hyperplastic mouse kidney unpublished data .
This can be explained by the fact that the highly
regulated ODC gene contains numerous potential reg-
ulatory sequences with strong homology to consensus
binding sites for diverse transcription factors that
enables a cross-talk between different signaling path-
w xways 41,42 .
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